Perioperative Nivolumab Improves EFS in Resectable NSCLC Perioperative Nivolumab Improves EFS in Resectable NSCLC

Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy only.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news